Log in

NASDAQ:OCRX - Ocera Therapeutics Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Average Volume1.11 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. Read More…

Industry, Sector and Symbol

Industry N/A
Current SymbolNASDAQ:OCRX
Previous SymbolNASDAQ:TZYM



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable

Receive OCRX News and Ratings via Email

Sign-up to receive the latest news and ratings for OCRX and its competitors with MarketBeat's FREE daily newsletter.

Ocera Therapeutics (NASDAQ:OCRX) Frequently Asked Questions

What is Ocera Therapeutics' stock symbol?

Ocera Therapeutics trades on the NASDAQ under the ticker symbol "OCRX."

How were Ocera Therapeutics' earnings last quarter?

Ocera Therapeutics Inc (NASDAQ:OCRX) announced its quarterly earnings data on Tuesday, November, 14th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.24). View Ocera Therapeutics' Earnings History.

Has Ocera Therapeutics been receiving favorable news coverage?

News headlines about OCRX stock have been trending somewhat positive on Sunday, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Ocera Therapeutics earned a daily sentiment score of 2.0 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near term. View News Stories for Ocera Therapeutics.

What other stocks do shareholders of Ocera Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ocera Therapeutics investors own include Biopharmx (BPMX), Heat Biologics (HTBX), Neovasc (NVCN), Synergy Pharmaceuticals (SGYP), Protalix Biotherapeutics (PLX), Celsion (CLSN), CytRx (CYTR), BIOLINERX LTD/S (BLRX), Cara Therapeutics (CARA) and Conatus Pharmaceuticals (CNAT).

Who are Ocera Therapeutics' key executives?

Ocera Therapeutics' management team includes the folowing people:
  • Linda S. Grais M.D., President, Chief Executive Officer, Director (Age 61)
  • Michael Byrnes, Principal Financial Officer, Chief Accounting Officer, Vice President - Finance, Treasurer (Age 38)
  • Stan Bukofzer M.D., Chief Medical Officer (Age 59)
  • Steven P. James, Lead Independent Director (Age 57)
  • Willard H. Dere M.D., Director (Age 63)
  • Nina S. Kjellson, Independent Director (Age 40)
  • Anne M. VanLent, Independent Director (Age 68)
  • Eckard Weber M.D., Independent Director (Age 66)

What is Ocera Therapeutics' official website?

The official website for Ocera Therapeutics is http://www.ocerainc.com/.

How can I contact Ocera Therapeutics?

Ocera Therapeutics' mailing address is 555 Twin Dolphin Dr Ste 615, REDWOOD CITY, CA 94065-2130, United States. The biopharmaceutical company can be reached via phone at +1-650-4750158 or via email at [email protected]

MarketBeat Community Rating for Ocera Therapeutics (NASDAQ OCRX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  333 (Vote Outperform)
Underperform Votes:  296 (Vote Underperform)
Total Votes:  629
MarketBeat's community ratings are surveys of what our community members think about Ocera Therapeutics and other stocks. Vote "Outperform" if you believe OCRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OCRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel